The success of Viagra initially drove a period of growth for the drug industry, but recent shifts present a complicated picture for investors. Off-patent alternatives are eroding revenue, and continued litigation add further complexity to the landscape. While certain companies could still gain from adjacent products, the broader direction sugges… Read More